INeo-Vac-P01 is under clinical development by Hangzhou Neoantigen Therapeutics and currently in Phase I for Hepatocellular Carcinoma. According to GlobalData, Phase I drugs for Hepatocellular Carcinoma have an 81% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how INeo-Vac-P01’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
INeo-Vac-P01 overview
iNeo-Vac-P01 is under investigation for the treatment of pancreatic cancer, colorectal cancer, melanoma, ovarian cancer, esophageal cancer, cholangiocarcinoma, hepatocellular carcinoma, intestinal cancer, gastric cancer and melanoma. The vaccine candidate comprises of personalized neoantigen peptides. It is administered through subcutaneous route.
It was also under development for the treatment of solid tumor, non-small cell lung cancer, colorectal cancer, ovarian cancer, melanoma and pancreatic cancer.
For a complete picture of INeo-Vac-P01’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
